MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. UHS
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Universal Health Services (UHS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Universal Health Services
NYSE•Healthcare•Medical Care Facilities
$180.75-0.46(<0.01%)After hours
Market Cap
$10.59B
P/E
6.9x
P/S
0.6x
P/B
1.4x

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities in the United States. It operates through Acute Care Hospital Services and Behavioral Health Care Services segments. The company's hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric, pharmacy, and/or behavioral health services. It also provides commercial health insurance services; capital resources; and various management services, including central purchasing, information services, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.

B

How this company scores

GoodMetricSide Score: 77/100

Strongest: Growth (23/25); weakest: Cash & Earnings Quality (14/25).

Profitability20/25
Growth23/25
Balance Sheet & Red Flags20/25
Cash & Earnings Quality14/25
Strengths
High ROERising earningsInterest easily coveredConsistent free cash flow

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 6.9x5y range 6.9x – 15.8x
P/E 6.9x · below its 20-quarter median

Currently below its 20-quarter median.

P/S · 0.6x5y range 0.5x – 1.0x
P/S 0.6x · near its 20-quarter median

Currently near its 20-quarter median.

P/B · 1.4x5y range 1.1x – 2.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.6x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume
Market Cap $10.59B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$18.11B
7Q
Q. Revenue
$4.64B
2Q
TTM EBITDA
$2.70B
7Q
TTM Op. Income
$2.06B
7Q
Q. Op. Income
$516.67M
3%
TTM Net Income
$1.53B
7Q
Q. Net Income
$358.45M
1%
EPS
$6.01
9%
Shares Out.
$59.66M
7Q
$18.11B in TTM revenue grew 10.0% YoY, reaching $4.64B last quarter. TTM EBITDA of $2.70B and TTM operating income of $2.06B show growth is flowing through to the bottom line. TTM net income of $1.53B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
14.7%
3%
Op. Margin
11.1%
4Q
Net Margin
7.7%
2Q
Op. margin of 11.1% is down 0.5% YoY — costs are rising relative to revenue. Net margin at 7.7% Across the last 8 quarters, operating margin has fallen for 4 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
6.9x
2Q
P/S Ratio
0.6x
2Q
P/B Ratio
1.4x
2Q
At 6.9x P/E, the stock trades below typical market levels. P/S of 0.6x and P/B of 1.4x provide additional context. P/E sits below typical market levels while revenue is growing. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$15.94B
7Q
Cash
$138.80M
1%
Long-Term Debt
$4.08B
10%
Book Value
$7.51B
7Q
D/E Ratio
0.5
16%
Debt/EBITDA
6.0
14%
With $15.94B in assets and $4.08B in long-term debt, D/E is 0.5and book value is $7.51B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 16% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$443.30M
19%
TTM Free Cash Flow
$845.40M
6%
FCF Margin
4.7%
15%
FCF / Net Income
0.6
23%
TTM FCF of $845.40M on $443.30M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 6% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 1.4x
· near its 20-quarter median

Currently near its 20-quarter median.